Yufan Wang
About
I am a Research Fellow in Health Economics at the University of Queensland’s Centre for the Business and Economics of Health (CBEH). My research focuses on the economic evaluation of varying healthcare interventions for cancer, with interests in exercise oncology, precision medicine, and implementation science. I am dedicated to advancing the long-term wellness of women following cancer treatment, specifically by identifying the cancer rehabilitation programs that provide the best value for money for this population. Additionally, I explore the role of therapeutic radiopharmaceuticals in cancer treatment, seeking to develop innovative cost-effective analysis that enable more robust evaluation of these novel therapies at the production stage.
Research Interests
Health technology assessment: systematic evaluation of efficacy and cost-effectiveness of novel health services
Value of information and implementation analysis: quantify decision uncertainty to optimise reimbursement decisions for high value-added health services
Structured expert elicitation: extract expert opinions into probabilistic distributions as evidence inputs for healthcare decision-modelling
Cancer economics: evaluate the health and economic impact of novel cancer therapies to promote equitable public access
Implementation Science: translate evidence-based practices into real-world healthcare and policy
Research Impact
I am an evaluator in the health technology assessment team at CBEH that evaluates submissions made to the Australian and Singapore governments to reimburse new drugs and medical devices.
In 2023, I published the first cost-utility analysis of a supervised exercise intervention designed for Australian women with early-stage endometrial cancer. The study shows that the proposed exercise program had a 99.5% likelihood to be cost-effective at a WTP threshold of AUD $50,000 over a time-horizon of 5 years.
I led the first co-designed Structured Expert Elicitation (SEE) with clinicians in exercise oncology, successfully eliciting three key uncertain quantities. This co-design approach enhanced the feasibility and acceptability of SEE in Australian clinical research.
I am collaborating with the ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) to develop new economic evaluation frameworks to assess the early value for money of manufactured radiopharmaceuticals at end-stage production.